CCTG-PR26
OPEN TO ACCRUAL
PIII Trial for Addition of Docetaxel to AR in Prostate Cancer (TRIPLE-SWITCH); Abi, Enza, Apa, Daro
UW20170
OPEN TO ACCRUAL
The Impact of DNA Repair Pathway Alt(s) Identified by ctDNA on Sensitivity to Rad223 in Bone mCRPC
UW23148
OPEN TO ACCRUAL
Ph2 single arm, SX-682 + Enza in ARPI-resistant mCRPC
UW24003
OPEN TO ACCRUAL
Clinical Validation of a Circulating Tumor Cell AR Therapy Resistance Assay in Men w/ mCRPC
UW25024
OPEN TO ACCRUAL
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC
UW25031
OPEN TO ACCRUAL
Ph1 study of JANX007 in mCRPC
UW25046
OPEN TO ACCRUAL
Ph 3 enzalutamide +/- mevrometostat (C2321008) in mCSPC
UW25130
OPEN TO ACCRUAL
Ph1 Study of KTX-2001 Alone And With Darolutamide In mCRPC
UW26047
OPEN TO ACCRUAL
Ph2 Talazoparib w/without Enzalutamide in mCRPC with HRR mutations after Progression on Abiraterone